Personal essays and analysis on Ozempic, weight-loss drugs, and the culture they created. Published intermittently. Always cultural, never prescriptive. Subscribe to the monthly letter to get the next one in your inbox.
Not medical advice — a cultural conversation. Ozemback is not affiliated with any pharmaceutical company or healthcare provider.
The cultural shorthand started in late 2024. Patients report blunted cravings — for food, alcohol, shopping, gambling, even Instagram. The mechanism is real: GLP-1 receptors are densely expressed in reward circuits. Here is the honest cultural read on what is signal and what is anecdote.
Read the essay →Food noise reached 1.8 billion TikTok views before it had a single validated instrument. Two scales, one published dispute between their authors, and still no biomarker.
Read more → Analysis · Mechanism journalismEvery drug in this class worked on how much goes in. Glucagon is the first receptor that changes what the body does with what is already there — and it has no therapeutic window of its own.
Read more → Analysis · Mechanism journalismAgonizing GIPR and antagonizing GIPR both produce roughly 20% weight loss. I think that stops being a paradox once you see GIP as a tolerability lever in the hindbrain, not a second weight-loss engine.
Read more → Analysis · Field analysisCompounding did not shrink when the GLP-1 shortage closed. It relocated one business model. I think the July 2026 committee votes, six of seven passed over the FDA's own scientists, matter more than the molecules.
Read more → Analysis · Field analysisThe FDA closed the GLP-1 shortage between October 2024 and May 2025. I think specialty pharmacy won the supply war and lost the distribution war in exactly that window.
Read more → Analysis · Field analysisMedicare's GLP-1 Bridge pays a pharmacy wholesale cost, minus the patient's $50, plus three dollars. I think that fee is the most revealing number the GLP-1 era has produced.
Read more → Analysis · Field analysisLillyDirect opened in January 2024, NovoCare Pharmacy in March 2025. The pharmacy counter did not lose a competition — two manufacturers removed it from the diagram, and cash-pay medicine only has one delivery system.
Read more → Analysis · Drug comparisonsOne trial in January 2022 put Wegovy against Saxenda under a single protocol and returned 15.8% against 6.4%. The commercial collapse followed, then the generic. Obesity medicine has no ritual for retiring a molecule.
Read more → Analysis · Drug comparisonsTwo oral GLP-1s, and an argument stuck on a weight-loss percentage drawn from trials that were never run against each other. The number that decides which pill matters is a manufacturing number.
Read more → Analysis · Drug comparisonsTirzepatide is the best obesity drug ever approved. The reason Lilly may spend the back half of the decade competing with itself is a molecule that adds a third receptor — and a higher ceiling.
Read more → Analysis · Drug comparisonsTirzepatide wins the scale by 6.5 points and it isn’t close. Semaglutide owns a placebo-controlled outcomes trial in 17,604 patients. Almost every version of this comparison drops one of those two facts.
Read more → Essay · NewFor a century the equation had two terms: diet and exercise. Then a generation woke up and the sentence had a third. An essay on what that third sentence does to a culture.
Read more →